Alyeska Investment Group L.P. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR)

Alyeska Investment Group L.P. acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,278,441 shares of the company's stock, valued at approximately $4,628,000. Alyeska Investment Group L.P. owned approximately 1.52% of Atyr PHARMA at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ATYR. Federated Hermes Inc. acquired a new position in Atyr PHARMA in the 4th quarter valued at about $53,093,000. Tikvah Management LLC acquired a new position in shares of Atyr PHARMA in the fourth quarter valued at approximately $8,908,000. Adage Capital Partners GP L.L.C. purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $3,620,000. Geode Capital Management LLC purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $3,229,000. Finally, Ally Bridge Group NY LLC acquired a new stake in Atyr PHARMA during the 4th quarter worth approximately $2,533,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ATYR has been the topic of a number of recent research reports. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Leerink Partners started coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $18.60.

Atyr PHARMA Stock Down 1.5 %

ATYR stock traded down $0.05 during midday trading on Friday, reaching $3.29. 925,655 shares of the company were exchanged, compared to its average volume of 907,177. The company has a market cap of $292.82 million, a price-to-earnings ratio of -3.50 and a beta of 0.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66. The stock's 50-day simple moving average is $3.27 and its 200 day simple moving average is $3.40.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. On average, equities analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.